Perioperative anticoagulant therapy in a patient with congenital antithrombinIII deficiency undergoing posterior spinal fusion

Kota Kubo, Eiki Hatori, Tomohiro Suhara, Takashige Yamada, Nobuyuki Katori, Tatsuya Yamada, Hiroshi Morisaki, Junzo Takeda

Research output: Contribution to journalArticle


A 22-year-old female was scheduled to undergo posterior thoracolumbar spinal fusion. She had been diagnosed with congenital antithrombinIII (AT-III) deficiency by the onset of pulmonary embolism and deep vein thrombosis after the first operation at the age of 18. Thereafter she had taken warfarin, 5 mg daily, until 4 days before the surgery. Preoperatively, we administered AT-III products to regulate AT-III activity. The posterior spinal fusion was performed successfully without surgical complications. Postoperatively, we continued administration of AT-III products to maintain AT-III activity above 75%. We also used low dose unfractionated heparin with AT-III by continuous intravenous infusion. Heparin was administered with dose adjustment to achieve a target activated partial thromboplastin time of 45 to 60 seconds. After the activated partial thromboplastin time was stabilized in the target range, we started warfarin therapy (target international normalized ratio, 1.5 to 2.5) on postoperative day 16 and stopped administration of heparin on postoperative day 19. There was no thrombosis complications during the perioperative period. Good anticoagulant management was achieved in a patient with congenital AT-III deficiency undergoing posterior spinal fusion.

Original languageEnglish
Pages (from-to)714-717
Number of pages4
JournalJapanese Journal of Anesthesiology
Issue number6
Publication statusPublished - 2013 Jun 1



  • Anticoagulant therapy
  • Congenital antithrombinIII deficiency
  • Deep vein thrombosis
  • Pulmonary embolism
  • Spinal fusion

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this